Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Abeona Therapeutics Inc ABEO

Healthcare Biotechnology
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The... see more

Recent & Breaking News (NDAQ:ABEO)

Abeona Therapeutics to Present at the Jefferies Healthcare Conference

GlobeNewswire June 1, 2023

Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023

GlobeNewswire May 22, 2023

Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

GlobeNewswire May 16, 2023

Abeona Therapeutics Reports First Quarter 2023 Financial Results

GlobeNewswire May 11, 2023

Abeona Therapeutics Announces Additional Phase 3 VIITAL(TM) Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting

GlobeNewswire May 11, 2023

Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

GlobeNewswire April 10, 2023

Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

GlobeNewswire March 29, 2023

Abeona Therapeutics Announces New Employee Inducement Grants

GlobeNewswire March 24, 2023

Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL(TM) Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting

GlobeNewswire March 16, 2023

Abeona Therapeutics Announces Update on AAV Ophthalmology Program

GlobeNewswire March 14, 2023

Abeona Therapeutics Reports Third Quarter 2022 Financial Results

GlobeNewswire November 14, 2022

Abeona Therapeutics Announces $35 Million Private Placement Financing

GlobeNewswire November 3, 2022

Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL(TM) Study of EB-101

GlobeNewswire November 3, 2022

Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL(TM) Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

GlobeNewswire October 19, 2022

Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL(TM) Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

GlobeNewswire October 4, 2022

Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit

GlobeNewswire September 22, 2022

Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference

GlobeNewswire September 13, 2022

Abeona Therapeutics Reports Second Quarter 2022 Financial Results

GlobeNewswire August 11, 2022

Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements

GlobeNewswire July 20, 2022

Abeona Therapeutics to Present at the Jefferies Healthcare Conference

GlobeNewswire June 6, 2022